WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124083
CAS#: 83712-60-1(sodium)
Description: Defibrotide sodium is a complex mixture of single stranded polydeoxyribonucleotides.
Hodoodo Cat#: H124083
Name: Defibrotide sodium
CAS#: 83712-60-1(sodium)
Chemical Formula: C20H21N4O6P
Exact Mass: 444.12
Molecular Weight: 444.380
Elemental Analysis: C, 54.06; H, 4.76; N, 12.61; O, 21.60; P, 6.97
Related CAS #: 83712-60-1(sodium) 1118915-78-8 (free acid),1402907-09-8 (disodium) 1118915-79-9 (monosodium),
Synonym: Defibrotide; STA-1474; 1118915-78-8; Defibrotide sodium; UNII-E1942E7K32;
IUPAC/Chemical Name: [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate
InChi Key: JNWFIPVDEINBAI-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H21N4O6P/c1-11(2)14-9-15(17(25)10-18(14)30-31(27,28)29)19-21-22-20(26)24(19)13-4-5-16-12(8-13)6-7-23(16)3/h4-11,25H,1-3H3,(H,22,26)(H2,27,28,29)
SMILES Code: O=P(O)(OC1=CC(O)=C(C(N2C3=CC4=C(N(C)C=C4)C=C3)=NNC2=O)C=C1C(C)C)O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 444.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Richardson PG, Triplett BM, Ho VT, Chao N, Dignan FL, Maglio M, Mohty M.
Defibrotide sodium for the treatment of hepatic veno-occlusive
disease/sinusoidal obstruction syndrome. Expert Rev Clin Pharmacol. 2018
Feb;11(2):113-124. doi: 10.1080/17512433.2018.1421943. Epub 2018 Jan 5. PMID:
29301447.
2: Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM,
Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER,
Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin
R, Gillio A, Bajwa R, D'Agostino RB Sr, Massaro J, Warren D, Miloslavsky M, Hume
RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ. Phase 3 trial of defibrotide
for the treatment of severe veno-occlusive disease and multi-organ failure.
Blood. 2016 Mar 31;127(13):1656-65. doi: 10.1182/blood-2015-10-676924. Epub 2016
Jan 29. PMID: 26825712; PMCID: PMC4817309.
3: Macciò A, La Nasa G, Oppi S, Madeddu C. Defibrotide Has a Role in COVID-19
Therapy. Chest. 2022 Aug;162(2):271-273. doi: 10.1016/j.chest.2022.04.143. PMID:
35940644; PMCID: PMC9353171.
4: Corbacioglu S, Topaloglu O, Aggarwal S. A Systematic Review and Meta-Analysis
of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal
Obstruction Syndrome. Clin Drug Investig. 2022 Jun;42(6):465-476. doi:
10.1007/s40261-022-01140-y. Epub 2022 May 20. PMID: 35594010; PMCID: PMC9188533.
5: Defibrotide for hepatic veno-occlusive disease. Aust Prescr. 2021
Apr;44(2):64. doi: 10.18773/austprescr.2021.010. Epub 2021 Mar 4. PMID:
33911337; PMCID: PMC8075747.
6: Aziz MT, Kakadiya PP, Kush SM, Weigel K, Lowe DK. Defibrotide: An
Oligonucleotide for Sinusoidal Obstruction Syndrome. Ann Pharmacother. 2018
Feb;52(2):166-174. doi: 10.1177/1060028017732586. Epub 2017 Sep 15. PMID:
28914546.
7: Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in
blood and marrow transplantation. Blood Adv. 2018 Jun 26;2(12):1495-1509. doi:
10.1182/bloodadvances.2017008375. Erratum in: Blood Adv. 2018 Aug 14;2(15):1853.
PMID: 29945939; PMCID: PMC6020812.